Era7 Bioinformatics

Era7 Bioinformatics

Granada, Spain· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Era7 Bioinformatics is a private, research-driven company offering specialized bioinformatics services focused on bacterial genomics and metagenomics. Its core business model is providing analytical services and tailored software, positioning it in the 'Services' and 'Platform' categories. While the company has established a portfolio of proprietary analysis tools like BG7 and MG7, its website content appears compromised with unrelated spam, indicating potential operational or reputational risks. The company is likely in an 'Early Revenue' stage, serving research and commercial clients in the genomics sector.

BioinformaticsGenetics & GenomicsAI / Machine Learning

Technology Platform

Suite of proprietary bioinformatics pipelines for bacterial genomics (BG7 for annotation, CG7 for comparative genomics, AG7 for genome closing, MG7 for metagenomics) and RNA-seq analysis, delivered via cloud computing and open-source frameworks.

Funding History

1
SeedUndisclosed

Opportunities

Growing demand for specialized bacterial genomics and metagenomics analysis driven by antimicrobial resistance research, human microbiome studies, and industrial biotechnology.
The shift to cloud-based bioinformatics and the increasing volume of NGS data create a need for scalable, expert analytical services.

Risk Factors

Severe reputational and operational risk due to a compromised website filled with irrelevant spam content, indicating potential neglect or security failure.
High competition in the bioinformatics services market and the need for continuous investment to keep pace with rapidly evolving sequencing technologies and analytical methods.

Competitive Landscape

Era7 competes in a crowded bioinformatics services market against large CROs, sequencing platform companies offering integrated analysis suites, academic core facilities, and numerous other specialized startups. Its differentiation is its specific focus on bacterial genomics, but maintaining a technological edge is challenging.